Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30934714 | 1.00 | MAPT (0.39) | MAPTPOLBMEN1KMT2ATHRB | |
| SCHEMBL27857856 | 0.76 | MAPT (0.34) | MAPTPOLBMEN1KMT2ATHRB | |
| SCHEMBL1506443 | 0.75 | MAPT (0.39) | MAPTPOLBMEN1KMT2ATHRB | |
| SCHEMBL1506526 | 0.74 | KMT2A (0.41) | MAPTPOLBMEN1KMT2ATHRB | |
| SCHEMBL30934943 | 0.74 | KMT2A (0.41) | MAPTPOLBMEN1KMT2ATHRB | |
| SCHEMBL19744030 | 0.74 | MAPT (0.35) | MAPTPOLBMEN1KMT2A | |
| SCHEMBL30934837 | 0.74 | MAPT (0.35) | MAPTPOLBMEN1KMT2A | |
| SCHEMBL11812742 | 0.72 | MEN1 (0.39) | MAPTMEN1KMT2ANTRK1LMNA | |
| SCHEMBL6420428 | 0.71 | MEN1 (0.33) | MAPTMEN1KMT2ANTRK1 | |
| SCHEMBL16659006 | 0.69 | MAPT (0.33) | MAPTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-01-30 | — | — | US | disclosed |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-11-19 | — | — | US | disclosed |
| CN-114127073-B | Imidazopyrimidines as EED inhibitors and use thereof | 密歇根大学董事会 | 2024-05-31 | — | — | CN | disclosed |
| US-20220227778-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-07-21 | — | — | US | disclosed |
| EP-3999510-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114127073-A | Imidazopyrimidines as EED inhibitors and uses thereof | 美国密歇根州立大学试剂中心 | 2022-03-01 | — | — | CN | disclosed |
| WO-2021011713-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-08-01 | — | — | US | disclosed |
| CN-109790166-A | imidazopyridine compounds for the treatment of cancer | 诺华股份有限公司 | 2019-05-21 | — | — | CN | disclosed |
| EP-3472166-A1 | IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221100-A1 | IMIDAZOPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, BMI1 | MAPT 877/4885POLB 2384/4885MEN1 630/4885 |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | EED, EEF1D, EEF1A1 | MAPT 4458/4885POLB 1957/4885MEN1 1520/4885 |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | EZH2, DOT1L, BMI1 | MAPT 877/4885POLB 2384/4885MEN1 630/4885 |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | MAPT 4458/4885POLB 1957/4885MEN1 1520/4885 |
| US-20220227778-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | MAPT 4458/4885POLB 1957/4885MEN1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.